- Home
- SKIN vs CADL Comparison
SKIN vs CADL Comparison
Compare SKIN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- CADL
- Stock Information
- Founded
- SKIN 1997
- CADL 1999
- Country
- SKIN United States
- CADL United States
- Employees
- SKIN N/A
- CADL N/A
- Industry
- SKIN Package Goods/Cosmetics
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- CADL Health Care
- Exchange
- SKIN Nasdaq
- CADL Nasdaq
- Market Cap
- SKIN 295.5M
- CADL 313.5M
- IPO Year
- SKIN N/A
- CADL 2021
- Fundamental
- Price
- SKIN $2.53
- CADL $4.79
- Analyst Decision
- SKIN Hold
- CADL Strong Buy
- Analyst Count
- SKIN 1
- CADL 5
- Target Price
- SKIN $1.25
- CADL $19.80
- AVG Volume (30 Days)
- SKIN 895.2K
- CADL 726.8K
- Earning Date
- SKIN 11-11-2025
- CADL 11-13-2025
- Dividend Yield
- SKIN N/A
- CADL N/A
- EPS Growth
- SKIN N/A
- CADL N/A
- EPS
- SKIN N/A
- CADL N/A
- Revenue
- SKIN $310,064,000.00
- CADL N/A
- Revenue This Year
- SKIN N/A
- CADL N/A
- Revenue Next Year
- SKIN $6.05
- CADL N/A
- P/E Ratio
- SKIN N/A
- CADL N/A
- Revenue Growth
- SKIN N/A
- CADL N/A
- 52 Week Low
- SKIN $0.78
- CADL $3.79
- 52 Week High
- SKIN $2.56
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- SKIN 67.00
- CADL 32.97
- Support Level
- SKIN $2.22
- CADL $4.81
- Resistance Level
- SKIN $2.51
- CADL $5.01
- Average True Range (ATR)
- SKIN 0.15
- CADL 0.30
- MACD
- SKIN 0.04
- CADL -0.08
- Stochastic Oscillator
- SKIN 95.16
- CADL 3.18
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.